Swedish Medical Center

EFFECTS OF GUSELKUMAB, A MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO THE P19-SUBUNIT OF INTERLEUKIN-23, ON DACTYLITIS AND ENTHESITIS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: POOLED RESULTS THROUGH WEEK 24 FROM TWO PHASE 3 STUDIES (2020) Mcgonagle D, Mcinnes I, Deodhar A, Schett G, Mease PJ, Shawi M, Kafka S, et al. Conference contribution Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5-year Results from the Phase 3 FUTURE 1 Study (2020) Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J, Hall S, Geusens P, et al. Journal article Secukinumab provides sustained improvements in the signs and symptoms in psoriatic arthritis: final 5-year efficacy and safety results from the FUTURE 1 Phase 3 trial (2019) Tahir H, Mease PJ, Kavanaugh A, Reimold A, Rech J, Hall S, Geusens P, et al. Conference contribution SECUKINUMAB PROVIDES RAPID AND SUSTAINED RESOLUTION OF ENTHESITIS IN PSORIATIC ARTHRITIS PATIENTS: POOLED ANALYSIS OF TWO PHASE 3 STUDIES, FUTURE 2 AND FUTURE 3 (2019) Coates LC, Mcgonagle D, Schett G, Mease PJ, Quebe-Fehling E, Asquith DL, Rasouliyan L, et al. Conference contribution Secukinumab in the treatment of psoriatic arthritis: Efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial (2018) Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J, Hall S, Geusens P, et al. Journal article 5-YEAR EFFICACY AND SAFETY OF APREMILAST TREATMENT IN SUBJECTS WITH PSORIATIC ARTHRITIS: POOLED ANALYSIS OF THE PALACE STUDIES (2018) Kavanaugh A, Gladman DD, Edwards CJ, Schett G, Guerette B, Delev N, Teng L, et al. Conference contribution Secukinumab Efficacy in Psoriatic Arthritis: Individual Patient Meta-Analysis of Four Phase 3 Trials in 2049 Patients (2018) Gottlieb AB, Mease PJ, Kirkham B, Nash P, Balsa A, Combe B, Rech J, et al. Conference contribution Secukinumab Provides Sustained Improvements in the Signs and Symptoms in Psoriatic Arthritis: Final 5 Year Efficacy and Safety Results from a Phase 3 Trial (2018) Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J, Hall S, Geusens P, et al. Conference contribution SECUKINUMAB EFFICACY IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: META-ANALYSIS OF 4 PHASE 3 TRIALS (2018) Mease P, Kirkham B, Nash P, Balsa A, Combe B, Rech J, Martin R, et al. Conference contribution Durability of apremilast response through 5 years of treatment in subjects with psoriatic arthritis (2018) Kavanaugh A, Gladman DD, Gomez-Reino JJ, Hall S, Lespessailles E, Mease PJ, Schett G, et al. Conference contribution